Treatment of cerebral amyloid angiopathy

• US 8,003,097 B2
• Filed: 07/28/2008
• Issued: 08/23/2011
• Est. Priority Date: 04/18/2007
• Status: Expired due to Fees

• Current Assignee: Janssen Sciences Ireland UC (Johnson & Johnson)
• Original Assignee: Janssen Alzheimer Immunotherapy (Johnson & Johnson), Wyeth LLC (Pfizer Inc.)
• Inventors: Zago, Wagner, Schroeter, Sally, Games, Kate Dora
• Primary Examiner(s): Kolker; Daniel E.
• Application Number:
  US12/181,238
• Publication Number:
  US 20090142270A1
• Time in Patent Office: 1,121 Days
• Field of Search: None
• US Class Current: 424/133.1
• CPC Class Codes: A01K 2267/0312 Animal model for Alzheimer's disease
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/70 characterized by effect upon binding to a cell or to an antigen

Abstract

The invention provides improved agents and methods for treatment of cerebral amyloid angiopathy (CAA) and methods to effect prophylaxis of CAA. The methods can treat CAA concurrently with Alzheimer'"'"'s disease or separately. The methods can effect prophylaxis of CAA concurrently with Alzheimer'"'"'s disease or separately. The methods involve administering antibody that is specific for the N-terminus of Aβ or an agent that can induce such an antibody.

Claims

1. A method of restoring cerebral vascular phenotype in a patient suffering from vascular Aβ

deposits, comprising administering an antibody that is specific for Aβ

in a treatment regime associated with efficacious vascular amyloid removal, wherein the administration of the antibody restores cerebral vascular phenotype, wherein the antibody binds to an epitope within residues 1-10 of Aβ and

the antibody is administered intravenously at a quarterly frequency at a dose of 0.5-1.5 mg/kg, or monthly at a dose of 0.1-1 mg/kg, or is administered subcutaneously at a frequency between weekly and monthly at a dose of between 0.01 mg/kg to 0.35 mg/kg and the antibody is administered at least for a year.

2. The method of claim 1, wherein the antibody binds within residues 1-5 of Aβ

.

3. The method of claim 1, wherein the antibody is a humanized, human, or chimeric antibody.

4. The method of claim 3, wherein the antibody is humanized 3D6 or humanized 12A11.

5. The method of claim 4, wherein the humanized 3D6 antibody is bapineuzumab.

6. The method of any one of claims 1 and 2, 5, further comprising monitoring cerebral vascular phenotype.

7. The method of claim 6, wherein the monitoring comprises quantification of vascular elements along the vessel perimeter.

8. The method of claim 7, wherein the vascular elements are selected from the group consisting of vessel layer thickness, vessel size, luminal perimeter, intensity, and the relative position of vessel elements.

9. A method of restoring cerebral vascular meningeal vessel phenotype from structural damage from amyloid induced structural changes comprising:

monitoring for amyloid induced structural changes involving degeneration and hyperplasia/hypertrophy of smooth muscle cells and extracellular matrix in the vessel walls, and

subcutaneously or intravenously administering an antibody that is specific for Aβ

in a treatment regime associated with efficacious vascular amyloid removal, wherein the administration of the antibody restores vessels to normal phenotype;

wherein the antibody binds to an epitope within residues 1-10 of Aβ

.

10. The method of claim 9, wherein the antibody binds within residues 1-5 of Aβ

.

11. The method of claim 9, wherein the antibody is a humanized, human, or chimeric antibody.

12. The method of claim 11, wherein the antibody is humanized 3D6 or humanized 12A11.

13. The method of claim 12, wherein the humanized 3D6 antibody is bapineuzumab.